Individuals suffering from Alzheimer’s disease (AD) exhibit dramatic reductions in the content of corticotropin-releasing factor (CRF), increased expression of CRF receptors (CRFRs) and abnormalities in neuronal morphology in affected brain areas.
In addition, AD patients show decreased concentrations of CRF in their cerebrospinal fluid, which may contribute to their cognitive impairment.
A high affinity CRF binding protein, designated CRF-BP, has been discovered in post-mortem brain samples from AD patients.
CRF-BP serves to bind and inactivate CRF, reducing the pool of “free CRF” available to bind CRFRs.
Two CRFRs, designated CRF-RI and CFR-RII, have been described and exhibit distinct brain localizations.
Applications:Suitable for use in Western Blot, Immunohistochemistry.
Other applications not tested.
Recommended Dilution:Western Blot: 1:500-1:2000Immunohistochemistry: 1:50-1:200Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4°C for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20°C.
Aliquots are stable for 12 months after receipt.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：50ul
Host：rabbit
Source Antibody：human
Grade：Affinity Purified
Purity：Purified by immunoaffinity chromatography.
Form：Supplied as a liquid PBS, 0.05% sodium azide, pH 7.2.
Specificity：Recognizes endogenous levels of CRF. Species Crossreactivity: Human, mouse, rat
Isotype：IgG
Calc Applications Abbrev：IHC WB
Calc Crossreactivity：Hu Mo Rt
Immunogen：Synthetic peptide corresponding to amino acids 121-170 of Human CRF.
